GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Effective Interest Rate on Debt %

Relief Therapeutics Holding (Relief Therapeutics Holding) Effective Interest Rate on Debt % : 11.85% (As of Jun. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Relief Therapeutics Holding's annualized positive value of Interest Expense for the quarter that ended in Jun. 2023 was $0.41 Mil. Relief Therapeutics Holding's average total debt for the quarter that ended in Jun. 2023 was $3.44 Mil. Therefore, Relief Therapeutics Holding's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 was 11.85%.


Relief Therapeutics Holding Effective Interest Rate on Debt % Historical Data

The historical data trend for Relief Therapeutics Holding's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Effective Interest Rate on Debt % Chart

Relief Therapeutics Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.64 4.81 11.54 6.45 5.09

Relief Therapeutics Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 4.77 52.08 -43.30 11.85

Competitive Comparison of Relief Therapeutics Holding's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Relief Therapeutics Holding's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Effective Interest Rate on Debt % falls into.



Relief Therapeutics Holding Effective Interest Rate on Debt % Calculation

Relief Therapeutics Holding's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  -0.167/( (3.273+3.289)/ 2 )
=-1  *  -0.167/3.281
=5.09 %

where

Total Debt  (A: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.81 + 0.463
=3.273

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.413 + 0.876
=3.289

Relief Therapeutics Holding's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2022 )+Total Debt  (Q: Jun. 2023 ))/ count )
=-1  *  -0.408/( (3.289+3.598)/ 2 )
=-1  *  -0.408/3.4435
=11.85 %

where

Total Debt  (Q: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.413 + 0.876
=3.289

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.607 + 0.991
=3.598

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Jun. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Relief Therapeutics Holding  (OTCPK:RLFTF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Relief Therapeutics Holding Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines